tetano
Editor, Senior Moderator
J Ultrasound Med
. 2020 Jun 1.
doi: 10.1002/jum.15367. Online ahead of print.
Lung Ultrasound Can Influence the Clinical Treatment of Pregnant Women With COVID-19
Murat Yassa[SUP] 1 [/SUP], Pinar Birol[SUP] 1 [/SUP], Ali Memis Mutlu[SUP] 1 [/SUP], Arzu Bilge Tekin[SUP] 1 [/SUP], Kemal Sandal[SUP] 1 [/SUP], Niyazi Tug[SUP] 1 [/SUP]
Affiliations
Abstract
Lung ultrasound (LUS) is an effective tool to detect and monitor patients infected with 2019 coronavirus disease (COVID-19). The use of LUS on pregnant women is an emerging trend, considering its effectiveness during the outbreak. Eight pregnant women with a diagnosis of COVID-19 confirmed by nasal/throat real-time reverse transcription polymerase chain reaction testing who underwent point-of-care LUS examinations after routine obstetric ultrasound are described. A routinely performed LUS examination revealed serious lung involvement in 7 cases: 2 were initially asymptomatic; 3 have chest computed tomography; 1 had initial negative real-time reverse transcription polymerase chain reaction results; and 1 had initial negative computed tomographic findings. Treatment for COVID-19 was either commenced or changed in 87.5% of the patients (n = 7 of 8) on LUS findings. Among patients with abnormal LUS findings, treatment was commenced in 5 patients (71.5%) and changed in 2 patients (28.5%). One normal and 7 abnormal LUS cases indicate the impact of routine LUS on the clinical outcome and treatment of pregnant women.
Keywords: COVID-19; lung ultrasound; pneumonia; pregnancy; severe acute respiratory syndrome novel coronavirus 2.
. 2020 Jun 1.
doi: 10.1002/jum.15367. Online ahead of print.
Lung Ultrasound Can Influence the Clinical Treatment of Pregnant Women With COVID-19
Murat Yassa[SUP] 1 [/SUP], Pinar Birol[SUP] 1 [/SUP], Ali Memis Mutlu[SUP] 1 [/SUP], Arzu Bilge Tekin[SUP] 1 [/SUP], Kemal Sandal[SUP] 1 [/SUP], Niyazi Tug[SUP] 1 [/SUP]
Affiliations
- PMID: 32478445
- DOI: 10.1002/jum.15367
Abstract
Lung ultrasound (LUS) is an effective tool to detect and monitor patients infected with 2019 coronavirus disease (COVID-19). The use of LUS on pregnant women is an emerging trend, considering its effectiveness during the outbreak. Eight pregnant women with a diagnosis of COVID-19 confirmed by nasal/throat real-time reverse transcription polymerase chain reaction testing who underwent point-of-care LUS examinations after routine obstetric ultrasound are described. A routinely performed LUS examination revealed serious lung involvement in 7 cases: 2 were initially asymptomatic; 3 have chest computed tomography; 1 had initial negative real-time reverse transcription polymerase chain reaction results; and 1 had initial negative computed tomographic findings. Treatment for COVID-19 was either commenced or changed in 87.5% of the patients (n = 7 of 8) on LUS findings. Among patients with abnormal LUS findings, treatment was commenced in 5 patients (71.5%) and changed in 2 patients (28.5%). One normal and 7 abnormal LUS cases indicate the impact of routine LUS on the clinical outcome and treatment of pregnant women.
Keywords: COVID-19; lung ultrasound; pneumonia; pregnancy; severe acute respiratory syndrome novel coronavirus 2.